CURE

Global X S&P Biotech ETF

About this ETF

Invests in an equally-weighted portfolio of small, mid and large-cap companies focused on genetic research, immunotherapy and vaccine development, rebalanced quarterly.

IssuerGlobal X

Management fee (MER)0.45% p.a.

Inception date8 Nov 2018

BenchmarkS&P Biotechnology Select Industry Index

Scout Score

57/100

Ranked #16 of 50 in Thematic

An independent score calculated by ETF Scout across 7 real-data factors (cost, diversification, tracking, liquidity, fund strength, performance, income), ranked against other funds in the same category.

Cost78

Diversification100

Tracking42

Liquidity22

Fund Strength47

Performance—

Income19

Strengths

Well diversified — top holdings are 14.5% of the fund, less concentrated than 100% of Thematic peers.
Low fee — 0.45% p.a., cheaper than 78% of Thematic funds.

Weaknesses

Below-average yield — 0.03%, lower than 81% of Thematic peers.
Lower liquidity — 0.24% bid/ask spread, wider than 78% of Thematic peers.

Performance (as of 5 Nov 2026)

Total returns, net of fees. Periods longer than 1 year are annualised.

1 Month-4.76%

3 Months-1.65%

YTD+16.47%

1 Year+26.94%

3 Years (p.a.)+24.40%

5 Years (p.a.)+3.63%

Price history

Cumulative return over the selected period, indexed to 0% at the start of the range.

Top holdings (as of 13 Aug 2026)

The fund's largest individual holdings, ranked by portfolio weight.